Supreet Kaur, MD

Novel Therapies in B cell lymphoma mainly Diffuse large B cell lymphoma, CLL and Primary CNS lymphoma

Associations

• Malignant Hematology

My research focuses on improving outcomes in lymphoid malignancies through the integration of chemotherapy, immunotherapy, targeted agents, and cellular therapies. I am particularly interested in developing rational therapeutic combinations that enhance efficacy while minimizing toxicity. A central component of my work involves measurable residual disease (MRD)-guided clinical trials designed to personalize therapy intensity and reduce treatment-related morbidity without compromising disease control. In parallel, I am committed to advancing clinical trial design to improve diversity, equity, and access. Through innovative trial frameworks and the integration of technological tools, my goal is to ensure that study populations reflect the patients we serve in routine practice. This approach strengthens the generalizability of trial results and enhances their real-world applicability. I also conduct real-world outcomes research and incorporate patient-reported outcomes to better understand health-related quality of life, treatment tolerability, and both short- and long-term symptom burden associated with lymphoma and its therapies across the survivorship continuum.

Clinical Trial 23735
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Condition: Malignant Hematology
Intervention: lisocabtagene maraleucel ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.